News
DVAX
--
0.00%
--
Top Pharmaceutical Stocks for Q3 2021
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q3 2021.
Investopedia · 2d ago
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Simply Wall St. · 3d ago
Dynavax to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
/PRNewswire/ --  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that , Chief Executive Officer, will present virtually at the Goldman Sachs 42nd Annual Global Healthcare Conference on ...
PR Newswire - PRF · 06/09 20:05
Oligonucleotide Therapy Global Market Report 2021: COVID 19 Growth And Change to 2030
Reportlinker.com announces the release of the report "Oligonucleotide Therapy Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06090627/?utm_source=GNW
GlobeNewswire · 06/09 09:33
Valneva Concludes Recruitment for COVID-19 Vaccine Candidate Trial
Benzinga · 06/03 19:32
Valneva Completes Recruitment for Phase 3 Study of COVID-19 Vaccine That Contains Dynavax Adjuvant
MT Newswires · 06/03 15:14
Dynavax Technologies Up 5% After Heplisav B Commercialization Agreement
By Michael Dabaie Dynavax Technologies Corp. shares were up 5% to $8.24 in Thursday morning trading after the company inked a commercialization agreement for...
marketwatch.com · 05/27 14:38
Dynavax, Bavarian Nordic Ink Distribution Pact For Hepatitis B Vaccine In Germany
Benzinga · 05/27 12:47
Dynavax inks deal for HEPLISAV B with Bavarian Nordic in Germany
Dynavax Technologies (DVAX) has entered into a commercialization agreement with Bavarian Nordic (BVNKF) for the marketing and distribution of HEPLISAV B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in Germany with an expected
Seekingalpha · 05/27 11:50
BRIEF-Dynavax Announces Agreement With Bavarian Nordic For Commercialization Of Heplisav B®, A Two Dose Adult Hepatitis B Adjuvanted Vaccine, In Germany
reuters.com · 05/27 11:29
Dynavax Announces Agreement With Bavarian Nordic For Commercialization Of HEPLISAV B; Financial Terms Not Disclosed
Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement
Benzinga · 05/27 11:05
Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany
EMERYVILLE, Calif., /PRNewswire/ --  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement with for the marketing and distribution of HEPLIS...
PR Newswire - PRF · 05/27 11:00
Dynavax Signs Deal With Bavarian Nordic for Commercialization of Adult Hepatitis B Vaccine in Germany
MT Newswires · 05/27 09:47
Bavarian Nordic Announces Marketing and Distribution Agreement with Dynavax to Launch HEPLISAV B(R) Hepatitis B Vaccine in Germany
COPENHAGEN, Denmark, May 27 2021 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has entered a partnership with Dynavax Technologies Corporation (Nasdaq: DVAX) a biopharmaceutical company focused on developing and commercializing novel vaccines for the marke...
Globe Newswire · 05/27 05:15
Dynavax to Present at the William Blair 41st Annual Growth Stock Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the William Bl...
PR Newswire · 05/19 20:05
India's Biological E To Make Johnson & Johnson's COVID-19 Shots: Reuters
Benzinga · 05/19 11:09
UPDATE 1-India's Biological E. to produce J&J COVID-19 vaccine
reuters.com · 05/18 15:58
India's Biological E. to make J&J vaccine alongside own shot, managing director says
reuters.com · 05/18 14:46
Clover Bio's COVID-19 vaccine candidate shows immune response against SARS-CoV-2 variants in mouse model
Clover Biopharmaceuticals announces positive preclinical data from its second-generation, protein-based COVID-19 vaccine candidate, a modified B.1.351 Spike ((S))-Trimer (B.1.351 S-Trimer).B.1.351 S-Trimer demonstrated broad neutralization against the orig...
Seekingalpha · 05/18 04:50
China's Clover says its COVID-19 vaccine candidate shows immune response in mice
reuters.com · 05/18 04:35
Webull provides a variety of real-time DVAX stock news. You can receive the latest news about Dynavax Techs through multiple platforms. This information may help you make smarter investment decisions.
About DVAX
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.